Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.4K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.4K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

498
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
498
Cholinesterases: Distribution and Function01:22

Cholinesterases: Distribution and Function

800
Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
800
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

1.4K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.3K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.3K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.7K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stability of Epinephrine in a Normal Saline Solution.

Anesthesia progress·2024
Same author

Behaviour support in dentistry: A Delphi study to agree terminology in behaviour management.

Community dentistry and oral epidemiology·2024
Same author

The Physical Compatibility of Glycopyrrolate and Rocuronium.

Anesthesia progress·2023
Same author

Medical Emergency Management in the Dental Office (MEMDO): A Pilot Study Assessing a Simulation-Based Training Curriculum for Dentists.

Anesthesia progress·2021
Same author

Cardiac Arrest Upon Induction of General Anesthesia.

Anesthesia progress·2021
Same author

Medical Management of Epiglottitis.

Anesthesia progress·2020
Same journal

Cornelia de Lange Syndrome and General Anesthesia for Dental Treatment: A Case Report.

Anesthesia progress·2026
Same journal

A Review of Current Literature of Interest to the Office-Based Anesthesiologist.

Anesthesia progress·2026
Same journal

Comparison of the Effects of Remimazolam and Propofol, With Epinephrine-containing Lidocaine, on Rocuronium-induced Muscle Relaxation.

Anesthesia progress·2026
Same journal

Desflurane-Induced Delayed Onset of Malignant Hyperthermia: A Case Report.

Anesthesia progress·2026
Same journal

Review of Oral Muscle Relaxants Used for Chronic Temporomandibular Disorder Pain.

Anesthesia progress·2026
Same journal

Perioperative Anesthetic Management for Dental Patients of Venezuelan Descent.

Anesthesia progress·2026
See all related articles

Related Experiment Video

Updated: Dec 7, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.4K

Pseudocholinesterase Deficiency Considerations: A Case Study.

Bryant W Cornelius1, Todd M Jacobs2

  • 1Assistant Professor and Program Director of Oral Maxillofacial and Dental Anesthesiology, The Ohio State University College of Dentistry and Wexner Medical Center, Columbus, Ohio.

Anesthesia Progress
|September 29, 2020
PubMed
Summary
This summary is machine-generated.

Pseudocholinesterase deficiency prevents proper metabolism of certain anesthesia drugs, leading to prolonged effects. Anesthesia providers must recognize and manage this rare genetic or acquired disorder.

Keywords:
Butyrylcholinesterase deficiencyDelayed emergenceGeneral anesthesiaPseudocholinesterase deficiencyResidual neuromuscular blockade

More Related Videos

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

20.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.5K

Related Experiment Videos

Last Updated: Dec 7, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.4K
In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

20.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.5K

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Genetics

Background:

  • Pseudocholinesterase deficiency is a rare disorder affecting drug metabolism.
  • It impairs the breakdown of neuromuscular blocking agents like succinylcholine and mivacurium.
  • This deficiency can be inherited or acquired due to comorbidities.

Purpose of the Study:

  • To summarize the pathophysiology of pseudocholinesterase deficiency.
  • To provide guidance for anesthesia providers in managing affected patients.
  • To illustrate a case study of delayed emergence from anesthesia.

Main Methods:

  • Review of pharmacologic and physiologic data.
  • Analysis of clinical presentation and anesthetic management.
  • Case study of a patient with prolonged emergence.

Main Results:

  • Patients with pseudocholinesterase deficiency experience prolonged paralysis after succinylcholine or mivacurium.
  • Delayed emergence from anesthesia is a key clinical sign.
  • Understanding the disorder is crucial for safe patient care.

Conclusions:

  • Pseudocholinesterase deficiency requires specific anesthetic considerations.
  • Early recognition and appropriate management are vital for patient safety.
  • Further awareness and education are needed for anesthesia professionals.